See the DrugPatentWatch profile for cosentyx

There is currently no scientific evidence to suggest that the MMR (measles, mumps, and rubella) vaccine causes issues when administered after Cosentyx (secukinumab) [1]. However, it is always important to consult with a healthcare provider before receiving any vaccinations or medications, as individual health situations can vary [2].

Cosentyx is a medication used to treat a number of conditions, including plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [3]. It is a type of drug called a monoclonal antibody, which works by targeting and blocking a specific protein in the body that contributes to inflammation [3].

The MMR vaccine, on the other hand, is a live attenuated vaccine that protects against measles, mumps, and rubella [4]. It is typically given to children in early childhood, but may also be recommended for adults who have not previously received the vaccine or who are at risk of exposure [4].

While there is no evidence to suggest that the MMR vaccine causes issues when administered after Cosentyx, it is important to note that live vaccines like the MMR vaccine can sometimes be less effective in people taking medications that suppress the immune system, like Cosentyx [5]. This is because these medications can affect the body's ability to mount an immune response to the vaccine [5]. However, this does not mean that the vaccine is contraindicated or that it will cause issues; it simply means that the vaccine may not provide as strong of protection as it would in someone not taking these medications [5].

In summary, there is no evidence to suggest that the MMR vaccine causes issues when administered after Cosentyx. However, it is always important to consult with a healthcare provider before receiving any vaccinations or medications, as individual health situations can vary.

Sources:

1. DrugPatentWatch.com. Cosentyx (secukinumab) [Internet]. DrugPatentWatch.com; [cited 2023 Feb 16]. Available from: <https://www.drugpatentwatch.com/drugs/cosentyx>.
2. Centers for Disease Control and Prevention. Vaccine Information Statements (VISs) [Internet]. Centers for Disease Control and Prevention; [cited 2023 Feb 16]. Available from: <https://www.cdc.gov/vaccines/hcp/vis/index.html>.
3. Novartis. Cosentyx (secukinumab) [Internet]. Novartis; [cited 2023 Feb 16]. Available from: <https://www.cosentyx.com/>.
4. Centers for Disease Control and Prevention. Measles, Mumps, and Rubella (MMR) Vaccine [Internet]. Centers for Disease Control and Prevention; [cited 2023 Feb 16]. Available from: <https://www.cdc.gov/vaccines/vpd/mmr/index.html>.
5. Centers for Disease Control and Prevention. General Best Practice Guidelines for Immunization: Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP) [Internet]. Centers for Disease Control and Prevention; [cited 2023 Feb 16]. Available from: <https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html>.